col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

97 Results       Page 1

Wiley: British Journal of Clinical Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2022―Nov―12 Management of acquired hemophilia A in severe Covid-19: Hemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis Georg Gelbenegger, Ludwig Traby, Nina Rahimi, Paul Knöbl
2 [GO] 2022―Nov―02 Communication is Crucial: Lessons from COVID-19 vaccination and pregnancy Christine Cole, Maria Tsakiroglou, Catriona Waitt
3 [GO] 2022―Oct―27 COVID-19 restrictions and the incidence and prevalence of prescription opioid use in Australia - a nation-wide study Monica Jung, Dickson Lukose, Suzanne Nielsen, J. Simon Bell, Geoffrey I. Webb, Jenni Ilomäki
4 [GO] 2022―Oct―10 Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19 - a phase 2a, open-label, single dose escalation study Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers, Cécile L. Berends, Gaby Tresch, Marianne Soergel, et al. (+10)
5 [GO] 2022―Oct―03 COVID-19: Clinical status of vaccine development till date Sunny Kumar, Malini Basu, Pratyasha Ghosh, Aafreen Ansari, Mrinal K. Ghosh
6 [GO] 2022―Sep―12 People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study Ivan Kodvanj, Jan Homolak, Vladimir Trkulja
7 [GO] 2022―Aug―30 Comparative assessment of viral dynamic models for SARS-CoV-2 for pharmacodynamic assessment in early treatment trials Akosua A. Agyeman, Tao You, Phylinda L. S. Chan, Dagan O. Lonsdale, Christoforos Hadjichrysanthou, Tabitha Mahungu, et al. (+6)
8 [GO] 2022―Aug―27 Prevalence of NSAID use among people with COVID-19 and the association with COVID-19 related outcomes: systematic review and meta-analysis M. D. Huilei Zhao, M. D. Shanshan Huang, M. D. Shan Huang, M. D. Fuwei Liu, B. D. Wen Shao, M. D. Kaibo Mei, et al. (+6)
9 [GO] 2022―Aug―25 Local Variation in Low Carbon Footprint Inhalers in Pre-COVID Pandemic Primary Care Prescribing Guidelines for Adult Asthma in England and its Potential Impact Adam J. Twigg, Alexander Wilkinson, James N. Smith
10 [GO] 2022―Aug―12 Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City Alex K. Lyashchenko, Yifan Yu, Donald J. McMahon, Robert Bies, Michael T. Yin, Serge Cremers
11 [GO] 2022―Jul―20 Recombinant protein subunit COVID-19 Vaccine Induced Guillain-Barre Syndrome in an adolescent: A case report Rachna Rohilla, Ashish Kumar Kakkar, Krishna Divyashree, Ritin Mohindra, Vikas Suri
12 [GO] 2022―Jul―13 Fluvoxamine for COVID-19 outpatients: For the time being, we might prefer to curb our optimism Vladimir Trkulja
13 [GO] 2022―Jun―28 Rapid Review and Meta-Analysis of Adverse Events Associated with Molnupiravir in Patients with COVID-19 Behnam Amani, Sara Zareei, Bahman Amani
14 [GO] 2022―May―28 Acute appendicitis in a patient immunised with COVID-19 vaccine: a case report with morphological analysis Ettore Marconi, Giada Crescioli, Roberto Bonaiuti, Lavinia Pugliese, Raffaella Santi, Gabriella Nesi, et al. (+3)
15 [GO] 2022―Apr―18 Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA Vaccine: A case report and brief literature review Ferdaous Chahed, Najah Ben Fadhel, Haifa Ben Romdhane, Monia Youssef, Seifeddine Ben Hammouda, Amel Chaabane, et al. (+2)
16 [GO] 2022―Apr―16 Analgesia and COVID-19 William F. Laughey, Imran Lodhi, Olutoba Sanni, Graham Pennick, Bruce Charlesworth
17 [GO] 2022―Mar―31 Efficacy of pharmacological interventions in COVID-19: A network meta-analysis Sandhiya Selvarajan, Annuja Anandaradje, Santhosh Shivabasappa, Deepthy Melepurakkal Sadanandan, N. Sreekumaran Nair, Melvin George
18 [GO] 2022―Mar―24 Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials Innocent G. Asiimwe, Sudeep P. Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed
19 [GO] 2022―Mar―10 Response to Dal-Ré and Holm's ethical concern regarding the UK PANORAMIC COVID-19 trial by the PANORAMIC Investigators Christopher C. Butler
20 [GO] 2022―Mar―02 Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it? Vladimir Trkulja
21 [GO] 2022―Feb―22 Ethical concern regarding the UK PANORAMIC COVID-19 trial Rafael Dal-Ré, Søren Holm
22 [GO] 2022―Feb―17 Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) Laure-Hélène Préta, Adrien Contejean, Francesco Salvo, Jean-Marc Treluyer, Caroline Charlier, Laurent Chouchana
23 [GO] 2022―Feb―08 Fluvoxamine for COVID-19 ICU patients? Vladimir Trkulja
24 [GO] 2022―Feb―05 Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis Adithan Ganesh, Michael D. Randall
25 [GO] 2022―Feb―02 Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of prospective randomised clinical studies Frank M. P. Haren, John G. Laffey, Antonio Artigas, Clive Page, Marcus J. Schultz, David Cosgrave, et al. (+12)
26 [GO] 2022―Jan―11 Pharmacokinetic characterization of favipiravir in patients with COVID-19 Rezzan Gülhan, Emel Eryüksel, Medine Gülçebi İdriz Oğlu, Yekta Çulpan, Aylin Toplu, Derya Kocakaya, et al. (+17)
27 [GO] 2022―Jan―05 Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients Frank M. P. Haren, Lex M. Loon, Anne Steins, Thomas L. Smoot, Caitlin Sas, Sabrina Staas, et al. (+19)
28 [GO] 2021―Dec―29 Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients Charlotte D. C. C. Heijden, Rob Heine, Emma J. Kooistra, Roger J. Brüggemann, Jesper W. J. Walburgh Schmidt, Elke P. L. M. Grouw, et al. (+3)
29 [GO] 2021―Dec―22 Association of Renin-Angiotensin-Aldosterone System inhibition with Covid-19 hospitalization and all-cause mortality in the UK Biobank Fatemeh Safizadeh, Thi Ngoc Mai Nguyen, Hermann Brenner, Ben Schöttker
30 [GO] 2021―Dec―10 Comment on “A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine” Sotaro Ozaka, Takashi Kobayashi, Kazunari Murakami
31 [GO] 2021―Nov―22 Coping with COVID: preparing prescribers during the pandemic Robin E. Ferner, Julie Mason, Hannah K. Vallance, Tanvi Choudhary, John F. Marriott, Jamie J. Coleman, Sarah K. Pontefract
32 [GO] 2021―Nov―01 Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls Martina Calusic, Robert Marcec, Lea Luksa, Ivan Jurkovic, Natasa Kovac, Slobodan Mihaljevic, Robert Likic
33 [GO] 2021―Oct―29 Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials Driton Vela, Zana Vela-Gaxha, Mjellma Rexhepi, Rozafa Olloni, Violeta Hyseni, Rajmonda Nallbani
34 [GO] 2021―Sep―24 Combination therapies for COVID-19: an overview of the clinical trials landscape Sola Akinbolade, Diarmuid Coughlan, Ross Fairbairn, Glenn McConkey, Helen Powell, Dapo Ogunbayo, Dawn Craig
35 [GO] 2021―Sep―12 Preparation for the next pandemic-A plea for a nationalized approach Adam Cohen
36 [GO] 2021―Aug―23 A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine Talia Walter, Saxon Connor, Catherine Stedman, Matthew Doogue
37 [GO] 2021―Aug―19 Promoting COVID-19 vaccination through music and drama-Lessons from early phase of the pandemic Bernard Appiah, Bhavneet Walia, Su Hyun Nam
38 [GO] 2021―Aug―18 Changes in antibiotic prescribing following COVID-19 restrictions: Lessons for post-pandemic antibiotic stewardship Malcolm B. Gillies, David P. Burgner, Lorraine Ivancic, Natasha Nassar, Jessica E. Miller, Sheena G. Sullivan, et al. (+4)
39 [GO] 2021―Aug―03 Development, evaluation and use of COVID-19 vaccines in older adults: Preliminary principles for the pandemic and beyond Sarah N. Hilmer, Mirko Petrovic, David G. Le Couteur, Janice B. Schwartz, Petra Thuermann
40 [GO] 2021―Jul―28 COVID-19 Acute Respiratory Distress Syndrome (ARDS): a Simulation Study of the Effects of Combination Therapy with Tocilizumab and Siltuximab Eileen B. Doyle, Darren Bentley, Michael G. Dodds
41 [GO] 2021―Jul―23 Science fiction has become reality: best practice for future viral pandemics Daniel F. B. Wright, Carl M. J. Kirkpatrick
42 [GO] 2021―Jul―17 Traditional medicines for COVID-19: Perspectives from clinical pharmacologists Getnet Yimer, Edmund Ekuadzi, Pius Fasinu, Andreia Cristina Melo, Goonaseelan (Colin) Pillai
43 [GO] 2021―Jun―26 Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels Pinar Bakir Ekinci, Emre Kara, Ahmet Gorkem Er, Ahmet Cagkan Inkaya, Kutay Demirkan, Omrum Uzun
44 [GO] 2021―Jun―08 Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed
45 [GO] 2021―May―15 Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia Silvia Corcione, Amedeo De Nicolò, Giorgia Montrucchio, Silvia Scabini, Valeria Avataneo, Chiara Bonetto, et al. (+8)
46 [GO] 2021―May―13 Interferon-α-2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019 Jiong Yu, Xuan Lu, Ling Tong, Xiaowei Shi, Jing Ma, Feifei Lv, et al. (+5)
47 [GO] 2021―Apr―28 Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom Emma Rezel-Potts, Abdel Douiri, Phil J. Chowienczyk, Martin C. Gulliford
48 [GO] 2021―Apr―26 Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: a propensity score-matched cohort study Janneke P. Spiegelenberg, Marleen M. H. J. Gelder, Martje L. Maas, Marcel M. C. Hovens, Anne Esselink, Anton S. M. Dofferhoff, et al. (+11)
49 [GO] 2021―Apr―23 Rethinking the role of Research Ethics Committees in the light of Regulation (EU) No 536/2014 on Clinical Trials and the COVID-19 pandemic Silvia Tusino, Maria Furfaro
50 [GO] 2021―Apr―23 Ethics of vaccination: should capability measures be used to inform SARS-CoV-2 vaccination strategies ? Michael R. Millar, Yannis Gourtsoyannis, Angelina Jayakumar
51 [GO] 2021―Apr―15 Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios Yawen Jiang, Dan Cai, Daqin Chen, Shan Jiang, Lei Si, Jing Wu
53 [GO] 2021―Apr―13 SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies? Marko Boskovic, William Migo, Robert Likic
54 [GO] 2021―Mar―25 Liver and kidney function in patients with Covid-19 treated with remdesivir Sylvia A. Laar, Mark G. J. Boer, Kim B. Gombert-Handoko, Henk-Jan Guchelaar, Juliette Zwaveling
55 [GO] 2021―Mar―24 Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults? Rafael Dal-Ré
56 [GO] 2021―Mar―20 Zinc supplementation as an adjunct therapy for COVID-19: challenges and opportunities Vidyasagar Chinni, Hanna El-Khoury, Marlon Perera, Rinaldo Bellomo, Daryl Jones, Damien Bolton, et al. (+2)
57 [GO] 2021―Mar―09 Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: A “two-edged sword” hypothesis Theocharis Koufakis, Symeon Metallidis, Pantelis Zebekakis, Kalliopi Kotsa
58 [GO] 2021―Feb―20 Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study Nicolas Hoertel, Marina Sánchez-Rico, Raphaël Vernet, Nathanaël Beeker, Antoine Neuraz, Jesús M. Alvarado, et al. (+9)
59 [GO] 2021―Feb―20 Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action Lakshmikirupa Sunderesan, Suvendu Giri, Himanshi Singh, Suvro Chatterjee
60 [GO] 2021―Feb―13 Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing? Robert Marcec, Robert Likic
61 [GO] 2021―Jan―28 No association between use of ACE inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study Roos S.G. Sablerolles, Freija E.F. Hogenhuis, Melvin Lafeber, Bob P.A. Loo, Sander D. Borgsteede, Eric Boersma, et al. (+2)
62 [GO] 2020―Dec―30 INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and Statistical Analysis Plan for an investigator-initiated international meta-trial of randomised studies Frank M.P. Haren, Alice Richardson, Hwan-Jin Yoon, Antonio Artigas, John G. Laffey, Barry Dixon, et al. (+23)
63 [GO] 2020―Dec―30 Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2 Kashyap Patel, Michael Dodds, Antonio Gonçalves, Mohamed A. Kamal, Craig R. Rayner, Carl M. Kirkpatrick, Patrick F. Smith
64 [GO] 2020―Dec―18 A possible increased risk of metamizole-associated neutropenia among COVID-19 patients Tsahi T. Lerman, Moshe Sagi, Yair Shafir, Liron Sheena, Eytan Cohen, Elad Goldberg, Ilan Krause
65 [GO] 2020―Dec―02 Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future Ester Calvo Fernández, Lucie Y. Zhu
66 [GO] 2020―Nov―27 Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: a scoping review Juan Pimentel, Cassandra Laurie, Anne Cockcroft, Neil Andersson
67 [GO] 2020―Nov―24 Pharmacokinetics under the COVID-19 Storm Venkatesh Pilla Reddy, Eman El-Khateeb, Heeseung Jo, Natalie Giovino, Emily Lythgoe, Shringi Sharma, et al. (+3)
68 [GO] 2020―Nov―21 Chasing COVID-19 chemotherapeutics without putting the cart before the horse Steven P. Rannard, Tom O. McDonald, Andrew Owen
69 [GO] 2020―Nov―21 Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - Systematic Review and Meta-Analysis Chang Chu, Shufei Zeng, Ahmed A. Hasan, Carl-Friedrich Hocher, Bernhard K. Kraemer, Berthold Hocher
70 [GO] 2020―Nov―13 Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs Sara Ferraro, Marco Tuccori, Irma Convertino, Giulia Valdiserra, Emiliano Cappello, Fabrizio Maggi, et al. (+2)
71 [GO] 2020―Oct―30 Risk Assessment of therapeutic agents under consideration to treat COVID-19 in Pediatric Patients and Pregnant Women Jeffrey S. Barrett
72 [GO] 2020―Oct―29 Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs Jun Shi, Yubo Xiao, Yiting Zhang, Donghao Geng, Danhua Cong, Kevin X. Shi, Richard J. Knapp
73 [GO] 2020―Oct―24 Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population - a Danish cohort study Bente Mertz Nørgård, Jan Nielsen, Torben Knudsen, Rasmus Gaardskær Nielsen, Michael Due Larsen, Line Riis Jølving, Jens Kjeldsen
74 [GO] 2020―Oct―21 Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis Rajith K.R. Rajoli, Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley, et al. (+17)
75 [GO] 2020―Oct―14 COVID-19 vaccines: the importance of transparency and fact-based education Adam F. Cohen, Joop Gerven, Juan Garcia Burgos, Anthonius Boer, Ron A. M. Foucher, H. Flore, et al. (+4)
76 [GO] 2020―Oct―13 Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic Daniela R. Junqueira, Brian H. Rowe
78 [GO] 2020―Sep―03 Beyond Dexamethasone, Emerging Immuno-Thrombotic Therapies for COVID-19 Melanie Peta Jensen, Marc George, Derek Gilroy, Reecha Sofat
79 [GO] 2020―Aug―31 Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team Karin B. Mirzaev, Yury Kiselev, Dmitriy V. Ivashchenko, Vitaly Otdelenov, Dmitry A. Sychev
80 [GO] 2020―Aug―25 Lessons for teaching from the pandemic Jan Strojil, Hana Suchánková
81 [GO] 2020―Aug―21 Prescribing in COVID-19 patients: Should we take into account inflammation? Catia Marzolini, Manuel Battegay, Parham Sendi, David J. Back
82 [GO] 2020―Aug―17 The COVID-19 Ibuprofen controversy; a systematic review of NSAIDs in adult acute lower respiratory tract infections Ricky Vaja, Jeffery Chan, Plinio Ferreira, Amer Harky, Luke J. Rogers, Hime H. Gashaw, et al. (+2)
83 [GO] 2020―Jul―21 ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19 Benjamin Batteux, Sandra Bodeau, Valérie Gras-Champel, Sophie Liabeuf, Jean-Philippe Lanoix, Jean-Luc Schmit, et al. (+6)
84 [GO] 2020―Jul―21 Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19 Michael G. Dodds, Rajesh Krishna, Antonio Goncalves, Craig R. Rayner
85 [GO] 2020―Jul―18 Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19 Ricardo Peña-Silva, Stephen B. Duffull, Andrew C. Steer, Sandra X. Jaramillo-Rincon, Amanda Gwee, Xiao Zhu
86 [GO] 2020―Jul―15 The impact of the global COVID-19 pandemic on the conduct of clinical trials. Return to normalcy by considering the practical impact of a structured ethical analysis Maurits F.J.M. Vissers, Adam F. Cohen, Joop M.A. Gerven, Geert Jan Groeneveld
87 [GO] 2020―Jul―13 Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials Emma H. Baker, Kamal Patel, Jonathan Ball, Sarah Edwards, Thomas S. Harrison, Arvind Kaul, et al. (+5)
88 [GO] 2020―Jul―08 Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19 Milo Gatti, Michele Fusaroli, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi
89 [GO] 2020―Jul―06 Potential role of IL-17 blocking agents in the treatment of severe COVID-19? Vedrana Bulat, Mirna Situm, Marija Delas Azdajic, Robert Likic
90 [GO] 2020―Jun―19 Model informed dosing of Hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and Gaps Pauline Thémans, Nicolas Dauby, Loïc Schrooyen, Faustine Lebout, Marc Delforge, Rakan Nasreddine, et al. (+9)
91 [GO] 2020―Jun―19 How to expedite early phase SARS-CoV-2 vaccine trials in pandemic setting - a practical perspective J.L. Plas, M. Roestenberg, A.F. Cohen, I.M.C. Kamerling
92 [GO] 2020―Jun―09 A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments Emma H. Baker, Danijela Gnjidic, Carl M.J. Kirkpatrick, Munir Pirmohamed, Daniel F.B. Wright, Anna Y. Zecharia
93 [GO] 2020―May―08 Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic Ahmet Emre Eşkazan
94 [GO] 2020―May―08 COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions David Back, Catia Marzolini, Catherine Hodge, Fiona Marra, Alison Boyle, Sara Gibbons, et al. (+2)
95 [GO] 2020―May―02 Off-target ACE2 ligands: possible therapeutic option for CoVid-19? Simone Brogi, Vincenzo Calderone
96 [GO] 2020―Apr―30 COVID-19 and (hydroxy)chloroquine-Azithromycin combination: Should we take the risk for our patients? Hervé Javelot, Wissam El-Hage, Guillaume Meyer, Guillaume Becker, Bruno Michel, Coraline Hingray
97 [GO] 2020―Apr―18 Dosing will be a key success factor in repurposing antivirals for COVID-19 Patrick F. Smith, Michael Dodds, Darren Bentley, Karen Yeo, Craig Rayner

97 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.025 sec